The Effect of Neuraxial Morphine (Duramorph) on Pain Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Advaita Punjala-Patel, MD
- Phone Number: 9198092145
- Email: apunjala@augusta.edu
Study Contact Backup
- Name: Linda Street, MD
- Email: lstreet@augusta.edu
Study Locations
-
-
South Carolina
-
N. Augusta, South Carolina, United States, 29860
- Recruiting
- Augusta University Medical Center
-
Contact:
- Advaita Punjala-Patel, MD
- Phone Number: 919-809-2145
- Email: apunjalapatel@augusta.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a second degree, third degree, or fourth degree perineal tear identified in the immediate postpartum period.
- Pregnant patients who received neuraxial anesthesia during their labor course
- Women >18 yo
Exclusion Criteria:
- Unwillingness to participate in the study
- Allergy to morphine
- Women with history of polysubstance abuse/narcotic abuse
- Women <18 yo
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Duramorph (Morphine)
2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
|
Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural.
This will be a one time dose immediately postpartum.
Other Names:
|
|
No Intervention: No intervention
Patient does not get any intervention.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postpartum pain
Time Frame: 24 hours postpartum
|
Pain is to be assessed using the Numeric Rating Scale.
Scale ranges from 1(no pain) to 10 (most pain).
This scale will be used at 24 hours.
|
24 hours postpartum
|
|
Delayed postpartum pain
Time Frame: 48 hours postpartum
|
Pain is to be assessed using the Numeric Rating Scale.
Scale ranges from 1(no pain) to 10 (most pain).
This scale will be used at 48 hours to assess for delayed postpartum pain.
|
48 hours postpartum
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of narcotics used
Time Frame: 24 hours postpartum
|
The number of narcotics will be calculated using the medical record number of the participant and by noting the narcotics that the patients received in a 24 hour time frame.
This is documented by the nursing staff.
|
24 hours postpartum
|
|
Amount of narcotics used
Time Frame: 48 hours postpartum
|
The number of narcotics will be calculated using the medical record number of the participant and by noting the narcotics that the patients received in a 48 hour time frame.
This is documented by the nursing staff.
|
48 hours postpartum
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1313375-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.